Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations

類似資料

• Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
  著者:: Sehgal, Kartik, 等
  出版事項: (2020)
• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  著者:: Vasconcelos, Pedro E.N.S., 等
  出版事項: (2020)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  著者:: Sehgal, Kartik, 等
  出版事項: (2018)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  著者:: Rangachari, Deepa, 等
  出版事項: (2017)
• Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes
  著者:: VanderLaan, Paul A., 等
  出版事項: (2017)